{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:14:00Z","timestamp":1793301240807,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.seminoncol.2025.152348","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T21:18:20Z","timestamp":1749503900000},"page":"152348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3568-0232","authenticated-orcid":false,"given":"Francesco","family":"Vitiello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goki","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Shimose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaekyung","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Finkelmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Yeong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Presa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Masi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhoon","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tovoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kumada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Scartozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Tamburini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Giuseppe","family":"Foschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Persano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Rossari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Foti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Camera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Cobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Aldrighetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cascinu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Casadei-Gardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Rimini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seminoncol.2025.152348_bib0001","unstructured":"H Sung, J Ferlay, RL Siegel, et al. 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Global Cancer Statistics."},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152348_bib0002","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152348_bib0003","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152348_bib0004","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/liv.12696","article-title":"Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients","volume":"35","author":"Weinmann","year":"2015","journal-title":"Liver Int"},{"issue":"15_suppl","key":"10.1016\/j.seminoncol.2025.152348_bib0005","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1200\/JCO.2018.36.15_suppl.4018","article-title":"Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): global OPTIMIS final analysis","volume":"36","author":"Peck-Radosavljevic","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152348_bib0006","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3390\/cancers11081084","article-title":"Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and child-Pugh A liver function: a proof-of-concept study","volume":"11","author":"Kudo","year":"2019","journal-title":"Cancers (Basel)."},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152348_bib0007","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Jordi Bruix; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"10126","key":"10.1016\/j.seminoncol.2025.152348_bib0008","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.seminoncol.2025.152348_bib0009","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seminoncol.2025.152348_bib0010","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1200\/JCO.2022.40.4_suppl.379","article-title":"Phase 3 randomized, open-label, multicenter study of tremelimumab and durvalumab as first-line therapy in patients with unresectable hepatocellular carcinoma: HIMALAYA","volume":"40","author":"Abou-Alfa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Number 17_suppl","key":"10.1016\/j.seminoncol.2025.152348_bib0011","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) vs Lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): first results from CheckMate 9DW","volume":"42","author":"Robert Galle","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152348_bib0012","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","article-title":"Tislelizumab vs Sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial","volume":"9","author":"Qin","year":"2023","journal-title":"JAMA Oncol"},{"issue":"10064","key":"10.1016\/j.seminoncol.2025.152348_bib0013","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"RESORCE investigators","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152348_bib0014","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152348_bib0015","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial\u00f9","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152348_bib0016","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152348_bib0017","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/liv.15753","volume":"44","author":"Tada","year":"2024","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152348_bib0018","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1016\/S1470-2045(23)00186-9","article-title":"HCC Special Interest Group of the Italian Association for the Study of the Liver. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept","volume":"24","author":"Vitale","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.seminoncol.2025.152348_bib0019","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"7854","key":"10.1016\/j.seminoncol.2025.152348_bib0020","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"issue":"10126","key":"10.1016\/j.seminoncol.2025.152348_bib0021","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.seminoncol.2025.152348_bib0022","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seminoncol.2025.152348_bib0023","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1200\/JCO.2022.40.4_suppl.379","article-title":"Phase 3 randomized, open-label, multicenter study of tremelimumab and durvalumab as first-line therapy in patients with unresectable hepatocellular carcinoma: HIMALAYA","volume":"40","author":"Abou-Alfa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152348_bib0024","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1016\/S1470-2045(23)00186-9","article-title":"HCC Special Interest Group of the Italian Association for the Study of the Liver. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept","volume":"24","author":"Vitale","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.seminoncol.2025.152348_bib0025","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.seminoncol.2025.152348_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.640578","article-title":"Platelet-mediated protection of cancer cells from immune surveillance\u2013possible implications for cancer immunotherapy","volume":"12","author":"Schmied","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152348_bib0027","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/s41416-021-01445-3","article-title":"The prognostic and diagnostic significance of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: a prospective controlled study","volume":"125","author":"Johnson","year":"2021","journal-title":"Br J Cancer"},{"issue":"23","key":"10.1016\/j.seminoncol.2025.152348_bib0028","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.3390\/cancers14235834","article-title":"Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab","volume":"14","author":"Wu","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152348_bib0029","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775425000405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775425000405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T09:37:01Z","timestamp":1750412221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775425000405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0093775425000405"],"URL":"https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152348","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152348"}}